{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:47:29Z","timestamp":1790650049710,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1124\/dmd.112.045971","type":"journal-article","created":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T04:16:38Z","timestamp":1339215398000},"page":"1765-1770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mechanism-Based Inactivation of Cytochrome P450 2B6 by Methadone through Destruction of Prosthetic Heme"],"prefix":"10.1016","volume":"40","author":[{"given":"Hemali T.","family":"Amunugama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Hollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.045971_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cpt1975173258","article-title":"Disposition of methadone in methadone maintenance","volume":"17","author":"Angg\u00e5rd","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.045971_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.105.004747","article-title":"Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?","volume":"34","author":"Blobaum","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/tx020052x","article-title":"Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein","volume":"15","author":"Blobaum","year":"2002","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045971_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1369-1600.2010.00274.x","article-title":"CYP2B6 and OPRM1 gene variations predict methadone-related deaths","volume":"16","author":"Bunten","year":"2011","journal-title":"Addict Biol"},{"key":"10.1124\/dmd.112.045971_bib5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0022-3565(24)29205-3","article-title":"Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2","volume":"299","author":"Chang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.045971_bib6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1124\/dmd.31.11.1391","article-title":"Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components","volume":"31","author":"Chatterjee","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/ALN.0b013e318164937c","article-title":"Understanding methadone metabolism: a foundation for safer use","volume":"108","author":"Clark","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.112.045971_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0090-9556(25)06658-9","article-title":"Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion","volume":"23","author":"Crowley","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0003-9861(86)90128-1","article-title":"Carbon tetrachloride and 2-isopropyl-4-pentenamide-induced inactivation of cytochrome P-450 leads to heme-derived protein adducts","volume":"244","author":"Davies","year":"1986","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.112.045971_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.112.045971_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1124\/dmd.111.038505","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction","volume":"39","author":"Foti","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib12","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1021\/bi200482g","article-title":"Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity","volume":"50","author":"Gay","year":"2011","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.112.045971_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1124\/dmd.112.045971_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/bj1840481","article-title":"Degradation of cytochrome P-450 haem by carbon tetrachloride and 2-allyl-2-isopropylacetamide in rat liver in vivo and in vitro. Involvement of non-carbon monoxide-forming mechanisms","volume":"184","author":"Guzelian","year":"1979","journal-title":"Biochem J"},{"key":"10.1124\/dmd.112.045971_bib15","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1021\/bi9808464","article-title":"Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4","volume":"37","author":"He","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.112.045971_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1021\/tx950177k","article-title":"Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital","volume":"9","author":"He","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045971_bib17","doi-asserted-by":"crossref","first-page":"25864","DOI":"10.1074\/jbc.271.42.25864","article-title":"Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants. Partitioning between heme and protein alkylation and epoxidation","volume":"271","author":"He","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.112.045971_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0090-9556(25)06773-X","article-title":"Phencyclidine iminium ion. NADPH-dependent metabolism, covalent binding to macromolecules, and inactivation of cytochrome(s) P-450","volume":"15","author":"Hoag","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045971_bib20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1021\/tx060198m","article-title":"Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: evidence for complex heme interactions","volume":"19","author":"Hutzler","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045971_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045971_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0300-483X(96)03549-4","article-title":"Interaction of methadone with substrates of human hepatic cytochrome P450 3A4","volume":"117","author":"Iribarne","year":"1997","journal-title":"Toxicology"},{"key":"10.1124\/dmd.112.045971_bib23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-3565(24)35013-X","article-title":"Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation","volume":"290","author":"Jones","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.045971_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/dmd.31.1.46","article-title":"The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine","volume":"31","author":"Jushchyshyn","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib25","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1124\/dmd.106.010579","article-title":"Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine","volume":"34","author":"Jushchyshyn","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib26","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nprot.2010.125","article-title":"A quantitative high-throughput 96-well plate fluorescence assay for mechanism-based inactivators of cytochromes P450 exemplified using CYP2B6","volume":"5","author":"Kenaan","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1124\/dmd.112.045971_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/tx960184o","article-title":"Mechanism-based inactivation of cytochrome P450 2B1 by N-benzyl-1-aminobenzotriazole","volume":"10","author":"Kent","year":"1997","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.112.045971_bib28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","article-title":"Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir","volume":"110","author":"Kharasch","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.112.045971_bib29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1742-1241.2008.01990.x","article-title":"The role of methadone in cancer pain treatment\u2014a review","volume":"63","author":"Leppert","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1124\/dmd.112.045971_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256276","article-title":"Interindividual variability of methadone response: impact of genetic polymorphism","volume":"12","author":"Li","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"10.1124\/dmd.112.045971_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.104.079608","article-title":"The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5","volume":"313","author":"Lin","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.045971_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/dmd.110.032474","article-title":"Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase)","volume":"38","author":"Lu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/0006-291X(82)90682-9","article-title":"Mechanisms of hydroxylation by cytochrome P-450: exchange of iron-oxygen intermediates with water","volume":"104","author":"Macdonald","year":"1982","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.112.045971_bib34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920009789895534","article-title":"Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6","volume":"10","author":"Mo","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.045971_bib35","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature","volume":"239","author":"Omura","year":"1964","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.112.045971_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/abbi.2001.2574","article-title":"A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function","volume":"395","author":"Scott","year":"2001","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.112.045971_bib37","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0090-9556(25)08458-2","article-title":"Formation of a metabolic intermediate complex of cytochrome P4502B1 by clorgyline","volume":"24","author":"Sharma","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-4347(00)00344-3","article-title":"Determination of methadone and its metabolites EDDP and EMDP in human hair by headspace solid-phase microextraction and gas chromatography-mass spectrometry","volume":"746","author":"Sporkert","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1124\/dmd.112.045971_bib39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm00266a009","article-title":"Urinary metabolites of dl-methadone in maintenance subjects","volume":"16","author":"Sullivan","year":"1973","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.112.045971_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.112.045971_bib41","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1177\/0091270006293753","article-title":"Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6","volume":"46","author":"Walsky","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.045971_bib42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.045971_bib43","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0090-9556(25)07959-0","article-title":"Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein","volume":"10","author":"Ward","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.045971_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/mol.109.059808","article-title":"tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance","volume":"76","author":"Zhang","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.112.045971_bib45","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.111.183111","article-title":"Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4\u2013CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex","volume":"338","author":"Zhang","year":"2011","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624227835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624227835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.045971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:13:01Z","timestamp":1739909581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624227835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0090955624227835"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.045971","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism-Based Inactivation of Cytochrome P450 2B6 by Methadone through Destruction of Prosthetic Heme","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.045971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}